



UCB completes sale of established brands and updates 2024 financial guidance

- Successful completion of the sale of two established brands, with proceeds categorized under "other revenue"
- Update of 2024 financial guidance, projecting revenue near €6 billion and an adjusted EBITDA margin expected now within the upper part of the range of 23.0-24.5%

Brussels (Belgium), 05 November 2024 – 07:00 (CET) – UCB is pleased to announce the successful completion of the sale of rights to two established brands, Atarax® and Nootropil® for Europe and selected countries in Latin-America and Asia-Pacific to ADVANZ PHARMA. In 2023, these products generated net sales of €64 million. This strategic portfolio decision, finalized in early November, represents another important step in UCB's ongoing efforts to optimize its product portfolio and concentrate on high-growth opportunities.

As a result of this transaction, with proceeds categorized as "other revenue," and along with the continued strong performance of key growth drivers BIMZELX® (bimekizumab) and RYSTIGGO® (rozanolixizumab), UCB is updating its 2024 financial guidance:

The company now anticipates revenue close to €6 billion, up from the prior guidance of the "upper end of the range of €5.5 - 5.7 billion". Additionally, UCB expects its adjusted EBITDA (earnings before interests, taxes, depreciation and amortization) margin to reach the upper part of the confirmed range of 23.0-24.5%, with core earnings per share now projected between €4.25-4.65, compared to the earlier expectation of €3.70-4.40.

"We are pleased with the successful closure of the sale, which, combined with the strong performance of our key growth drivers, enhances our outlook for 2024," said Sandrine Dufour, CFO of UCB. "This reflects our balanced strategy of managing our portfolio of established brands while continuing investing in global launches and innovation, positioning us to achieve our ambitious targets for 2025 and beyond."

UCB will report its full-year 2024 results on 27 February 2025 and will provide financial guidance for 2025.

For further information, contact UCB:

Investor Relations

Antje Witte

T: +32.2.559.94.14

antje.witte@ucb.com

Sahar Yazdian

T: +32 2 559 9137

sahar.yazdian@ucb.com





Corporate Communications

Laurent Schots

T: +32.2.559.92.64

laurent.schots@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9 000 people in approximately 40 countries, the company generated revenue of € 5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

Forward looking statements

This press release contains forward-looking statements, including, without limitation, statements containing the words "potential", "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this press release.

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars and pandemics, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that





UCB News

implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems.

Given these uncertainties, you are cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this press release, and do not reflect any potential impacts from the evolving conflicts, wars, pandemics, as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB.

UCB expressly disclaims any obligation or duty to update any forward-looking statements in this press release, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

